Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain

被引:13
|
作者
Hua, Yaping [1 ]
Azeem, Waqas [1 ,2 ]
Shen, Yunheng [3 ]
Zhang, Shoude [4 ]
Olsen, Jan R. [1 ]
Oyan, Anne M. [1 ]
Ke, Xisong [1 ]
Zhang, Weidong [3 ]
Kalland, Karl-Henning [1 ,2 ,5 ]
机构
[1] Univ Bergen, Dept Clin Sci, Bergen, Norway
[2] Univ Bergen, Ctr Canc Biomarkers, Bergen, Norway
[3] Second Mil Med Univ, Coll Pharm, Shanghai, Peoples R China
[4] Qinghai Univ, State Key Lab Plateau Ecol & Agr, Xining, Qinghai, Peoples R China
[5] Haukeland Hosp, Dept Microbiol, Bergen, Norway
来源
PHARMACOLOGY RESEARCH & PERSPECTIVES | 2018年 / 6卷 / 06期
关键词
amino-terminal domain; androgen receptor; drug development; prostate cancer; STAT3; PROSTATE-CANCER; GENE-EXPRESSION; SPLICE VARIANTS; INTERLEUKIN-6; ANTIANDROGEN; RESISTANCE; ENZALUTAMIDE; ABIRATERONE; GENERATION; GROWTH;
D O I
10.1002/prp2.437
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Prostate cancer (PCa) often recurs as incurable castration-resistant prostate cancer (CRPC) after the failure of androgen deprivation therapy. CRPC development relies on androgen receptor (AR) signaling. The IL6/STAT3 pathway is also a key driver of CRPC. The crosstalk between IL6/STAT3 and the AR pathways provides opportunities to explore next-generation agents to treat PCa. Through screening of around 600 natural compounds in our newly established prostate tumorigenesis model, potential STAT3 signaling inhibitors were found and additionally examined for effects on AR signaling. The small molecular compound 154 exhibited dual effects on IL6/STAT3 and AR pathways. We show here that compound 154 inhibits AR and STAT3 transcriptional activity, reduces the expression of phosphorylation of STAT3 (Y705) and downregulates the mRNA levels of AR target genes. Compound 154 also inhibits protein expression of AR and AR splice variants (ARv567es and AR-V7) without altering AR mRNA levels. Compound 154 binds to AR directly, but not to STAT3 and is identified as an antagonist of the AR amino-terminal domain (NTD) by disrupting protein-protein interactions between STAT3 and the AR NTD. Moreover, compound 154 does not reduce AR nuclear translocation. Compound 154 possesses the potential to become a leading compound in novel therapies against CRPC.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation - Influence of structure-stabilizing solutes and protein-protein interactions
    Reid, J
    Kelly, SM
    Watt, K
    Price, NC
    McEwan, IJ
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (22) : 20079 - 20086
  • [32] Olive polyphenol, hydroxytyrosol, exerts anti-tumor effects in prostate cancer cells by targeting Akt, STAT3 and AR signaling
    Bhardwaj, Arun
    Singh, Seema
    Srivastava, Sanjeev K.
    Arora, Sumit
    Reed, Eddie
    Singh, Ajay P.
    CANCER RESEARCH, 2012, 72
  • [33] TARGETING ANDROGEN RECEPTOR FOR GLIOBLASTOMA: A NOVEL RADIOSENSITIZING THERAPY THROUGH TGF-B/LIF/STAT3 PATHWAY AND IMMUNOMODULATION
    Khan, Rubayat
    Zhao, Nan
    Zhang, Chi
    NEURO-ONCOLOGY, 2023, 25
  • [34] A Small Molecule Compound Targeting STAT3 DNA-Binding Domain Inhibits Cancer Cell Proliferation, Migration, and Invasion
    Huang, Wei
    Dong, Zizheng
    Wang, Fang
    Peng, Hui
    Liu, Jing-Yuan
    Zhang, Jian-Ting
    ACS CHEMICAL BIOLOGY, 2014, 9 (05) : 1188 - 1196
  • [35] Discovery of ETS-007, a first-in-class degrader targeting N-terminal domain of androgen receptor derived from AR liquid-liquid phase separation inhibitor
    Li, Yingjie
    Fei, Mingyue
    Miao, Yingke
    Feng, Lijian
    Fan, Xiaofei
    Li, Jinping
    Chen, Yaozhong
    Xu, Ming
    Cui, Wenqi
    Zheng, Qiangang
    Zhu, Jidong
    CANCER RESEARCH, 2024, 84 (06)
  • [36] Targeting the A3 adenosine receptor for cancer therapy: Inhibition of prostate carcinoma cell growth by A3AR agonist
    Fishman, P
    Bar-Yehuda, S
    Ardon, E
    Rath-Wolfson, L
    Barrer, F
    Ochaion, A
    Madi, L
    ANTICANCER RESEARCH, 2003, 23 (3A) : 2077 - 2083
  • [37] The Small Molecule Antagonist KCI807 Disrupts Association of the Amino-terminal Domain of the Androgen Receptor with ELK1 by Modulating the Adjacent DNA Binding Domain br
    Soave, Claire
    Ducker, Charles
    Islam, Naeyma
    Kim, Seongho
    Yurgelevic, Sally
    Nicely, Nathan I.
    Pardy, Luke
    Huang, Yanfang
    Shaw, Peter E.
    Auner, Gregory
    Dickson, Alex
    Ratnam, Manohar
    MOLECULAR PHARMACOLOGY, 2023, 103 (03) : 211 - 220
  • [38] Targeting the SH2 domain of Stat3 with phosphopeptide mimetic prodrugs leads to tumor growth inhibition and down-regulation of phosphoTyr705 Stat3 and angiogenic pathways
    McMurray, J.
    Klostergaard, J.
    Auzenne, E. J.
    Liao, W. S. L.
    Lu, Z.
    Mandal, P. K.
    Ramesh, R.
    Shanker, M.
    Scott, A. W.
    EJC SUPPLEMENTS, 2010, 8 (07): : 134 - 134
  • [39] A novel multifunctional motif in the amino-terminal A/B domain of T3Rα modulates DNA binding and receptor dimerization
    Hadzic, E
    Habeos, I
    Raaka, BM
    Samuels, HH
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (17) : 10270 - 10278
  • [40] Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain
    Shihong Peng
    Jie Wang
    Huang Chen
    Pan Hu
    Xiao-Long He
    Yundong He
    Minna Wang
    Wenshu Tang
    Qiurui He
    Ying-Ying Wang
    Jiayi Xie
    Dandan Guo
    Shancheng Ren
    Mingyao Liu
    Wen-Wei Qiu
    Zhengfang Yi
    Cell Biology and Toxicology, 2020, 36 : 399 - 416